ARS Pharmaceuticals, Inc Cash Flow Reinvestment Rate
ARS Pharmaceuticals, Inc cash flow reinvestment rate. ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Reinvestment Rate of 2.43x as of December 2024, reinvesting $102.06 Million (capex $302.00K plus investments $-101.76 Million) from operating cash flow of $42.00 Million. Explore ARS Pharmaceuticals, Inc (SPRY) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of ARS Pharmaceuticals, Inc (2020–2024)
Cash flow reinvestment rate of ARS Pharmaceuticals, Inc from 2020 to 2024. Historical reinvestment intensity for ARS Pharmaceuticals, Inc across 2 annual periods. Explore SPRY capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
ARS Pharmaceuticals, Inc Cash Flow Reinvestment Rate by Year (2020–2024)
ARS Pharmaceuticals, Inc cash flow reinvestment rate by year from 2020 to 2024. Year-by-year capital reinvestment analysis for ARS Pharmaceuticals, Inc. For the full cash flow conversion analysis, see SPRY cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.87x | $106.66 Million | $13.55 Million | $563.00K | ▲ +7688.0% |
| 2020 | 0.10x | $917.00K | $9.07 Million | $917.00K | — |